EURURO Vol. 72 No. 4

623 656

5. Conclusions
Vessel-sparing radiotherapy for men with localized prostate
cancer resulted inexcellent long-termpreservationof erectile
function and tumor control. Only 12% of the cohort at 5 yr had
profound erectile dysfunction unresponsive to the use of
sexual aids, and 87% of baseline potent men were able to
achieve erections firm enough for intercourse 2 yr after
treatment. The utilization of vessel-sparing radiotherapy is
feasible and safe and appears to be more effective than
historical controls or model-predicted rates of potency
preservation, and thuswarrants amulticenter validation trial.
Author contributions: Daniel E. Spratt had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Spratt, Lawrence, McLaughlin, Winfield,
Schipper, Narayana, Evans.
Acquisition of data: Spratt, Lee, Dessa, Narayana, Evans, Liss, McLaughlin,
Winfield.
Analysis and interpretation of data: Spratt, Lee, Dessa, Schipper,
McLaughlin, Narayana, Evans, Liss, Lawrence, Winfield.
Drafting of the manuscript: Spratt, Lee, Dessa, Narayana, Evans, Liss,
Lawrence, Schipper, Winfield, McLaughlin.
Critical revision of the manuscript for important intellectual content: All
authors.
Statistical analysis: Schipper, Spratt.
Obtaining funding: None.
Administrative, technical, or material support: Spratt, Lawrence, McLaugh-
lin.
Supervision: Spratt, Lawrence, McLaughlin, Schipper.
Other: None.
Financial disclosures: Daniel E. Spratt certifies that all conflicts of interest,
including specific financial interests and relationships and affiliations
relevant to the subjectmatter ormaterials discussed in themanuscript (eg,
employment/affiliation, grants or funding, consultancies, honoraria, stock
ownership or options, expert testimony, royalties, or patents filed,
received, or pending), are the following: Daniel E. Spratt is funded by
the Prostate Cancer Foundation and has served on an advisory board for
Dendreon. The remaining authors have nothing to disclose.
Funding/Support and role of the sponsor: None.
Acknowledgments: Daniel E. Spratt would like to thank the Prostate
Cancer Foundation for their continual support.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
.
References
[1]
[2]
.
[3]
.
[4]
.
[5]
[6]
.
[7]
[8]
[9]
.
[10]
[11]
.
[12]
.
[13]
.
[14]
[15]
[16]
.
[17]
.
[18]
[19]
[20]
[21]
.
[22]
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 1 7 – 6 2 4 623